Rigel Pharmaceuticals Inc.
RIGL | NASDAQ
$47.09
+$0.45 (+0.96%)
At close: Sep 21, 2026, 4:00 PM ET
$47.09
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 2.10 | 16.99 | -10.07 | -4.41 | -24.09 | -19.44 |
PEG Ratio | 0 | -0.10 | 0.17 | -0.02 | 0.62 | 0.35 |
PS Ratio | 2.62 | 1.65 | 2.16 | 2.15 | 3.03 | 5.44 |
PB Ratio | 1.97 | 89.93 | -8.81 | -18.99 | 14.87 | 17.36 |
P/FCF Ratio | 10.18 | 9.52 | -12.16 | -3.48 | 86.04 | -11.05 |
P/OCF Ratio | 10.18 | 9.40 | -43.93 | -3.51 | 76.86 | -11.32 |
OCF/S Ratio | 25.71 | 17.55 | -4.91 | -61.34 | 3.94 | -48.04 |
Debt / Equity Ratio | 0.14 | 18.24 | -2.11 | -3.05 | 1.01 | 1.15 |
Quick Ratio | 2.30 | 2.04 | 1.76 | 1.64 | 2.33 | 2.14 |
Current Ratio | 2.42 | 2.13 | 1.86 | 1.78 | 2.43 | 2.18 |
Asset Turnover | 0.57 | 1.09 | 1 | 0.90 | 0.89 | 0.98 |
Interest Coverage | 17.14 | 3.06 | -2.98 | -14.99 | -2.57 | -21.41 |
Return on Equity | 93.75% | 531.78% | 87.60% | 430.18% | -58.98% | -87.42% |
Return on Assets | 71.46% | 10.66% | -21.40% | -43.62% | -10.71% | -26.95% |
Return on Invested Capital | 28.21% | 21.28% | -28.51% | -79.13% | -10.99% | -37.07% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 93.33% | 89.60% | 93.92% | 98.55% | 99.27% | 99.18% |
Net Profit Margin | 124.72% | 9.75% | -21.47% | -48.71% | -12% | -27.38% |
Pretax Profit Margin | 41.40% | 10.24% | -21.47% | -48.71% | -11.60% | -27.38% |
Operating Profit Margin | 42.63% | 13.49% | -17.53% | -46.20% | -8.37% | -26.67% |
FCF Margin | 25.71% | 17.33% | -17.75% | -61.72% | 3.52% | -49.20% |
EBITDA Margin | 44.71% | 15.90% | -14.53% | -44.80% | -7.56% | -25.49% |
Add to Watchlist
Select watchlists to add or remove RIGL